Concepts (157)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Data Interpretation, Statistical | 3 | 2018 | 657 | 1.00 | Why? |
| Biostatistics | 2 | 2018 | 116 | 0.83 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2021 | 533 | 0.56 | Why? |
| Dengue | 7 | 2018 | 1565 | 0.51 | Why? |
| Human Migration | 1 | 2014 | 133 | 0.51 | Why? |
| Effect Modifier, Epidemiologic | 1 | 2012 | 39 | 0.50 | Why? |
| Causality | 2 | 2017 | 857 | 0.49 | Why? |
| Rotavirus Infections | 3 | 2018 | 355 | 0.38 | Why? |
| Dengue Vaccines | 3 | 2018 | 123 | 0.35 | Why? |
| Aedes | 4 | 2018 | 380 | 0.34 | Why? |
| Ebolavirus | 1 | 2014 | 834 | 0.34 | Why? |
| Research Design | 2 | 2020 | 5830 | 0.29 | Why? |
| Dengue Virus | 5 | 2018 | 910 | 0.29 | Why? |
| Rotavirus Vaccines | 2 | 2017 | 203 | 0.28 | Why? |
| Zika Virus Infection | 4 | 2018 | 1920 | 0.26 | Why? |
| Chikungunya Fever | 2 | 2018 | 345 | 0.26 | Why? |
| Models, Statistical | 4 | 2020 | 5312 | 0.25 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2014 | 1475 | 0.25 | Why? |
| Mosquito Vectors | 4 | 2018 | 351 | 0.24 | Why? |
| Family Characteristics | 7 | 2021 | 2551 | 0.24 | Why? |
| Influenza Vaccines | 4 | 2020 | 2941 | 0.24 | Why? |
| Mosquito Control | 2 | 2018 | 237 | 0.19 | Why? |
| Insect Control | 1 | 2018 | 17 | 0.18 | Why? |
| Patient-Specific Modeling | 1 | 2018 | 60 | 0.18 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2020 | 10649 | 0.18 | Why? |
| Vaccination | 4 | 2019 | 19050 | 0.18 | Why? |
| Cholera Vaccines | 1 | 2018 | 56 | 0.17 | Why? |
| Vaccines | 2 | 2018 | 3692 | 0.17 | Why? |
| Chikungunya virus | 2 | 2018 | 339 | 0.17 | Why? |
| Arbovirus Infections | 1 | 2018 | 104 | 0.17 | Why? |
| Insecticides | 1 | 2018 | 178 | 0.16 | Why? |
| Clinical Trials as Topic | 3 | 2020 | 7330 | 0.15 | Why? |
| Neisseria meningitidis | 1 | 2017 | 229 | 0.15 | Why? |
| Influenza, Human | 5 | 2020 | 10779 | 0.15 | Why? |
| Disease Outbreaks | 8 | 2020 | 27595 | 0.15 | Why? |
| Caliciviridae Infections | 1 | 2018 | 229 | 0.14 | Why? |
| Cholera | 1 | 2018 | 189 | 0.14 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.14 | Why? |
| Meningococcal Infections | 1 | 2017 | 216 | 0.14 | Why? |
| Norovirus | 1 | 2018 | 294 | 0.14 | Why? |
| Antibody-Dependent Enhancement | 1 | 2017 | 413 | 0.13 | Why? |
| Africa, Western | 1 | 2014 | 363 | 0.13 | Why? |
| Child, Preschool | 12 | 2021 | 36283 | 0.13 | Why? |
| Stochastic Processes | 2 | 2017 | 369 | 0.12 | Why? |
| Mexico | 5 | 2018 | 2787 | 0.12 | Why? |
| Communicable Diseases, Imported | 1 | 2020 | 843 | 0.11 | Why? |
| Seasons | 3 | 2019 | 4071 | 0.11 | Why? |
| Infant | 9 | 2021 | 30274 | 0.11 | Why? |
| Research Personnel | 1 | 2021 | 1037 | 0.11 | Why? |
| Zika Virus | 3 | 2018 | 1924 | 0.10 | Why? |
| Models, Biological | 3 | 2020 | 4907 | 0.10 | Why? |
| Child | 14 | 2021 | 70012 | 0.10 | Why? |
| Immunity, Herd | 1 | 2017 | 1011 | 0.10 | Why? |
| Disease Transmission, Infectious | 1 | 2012 | 9044 | 0.09 | Why? |
| Public Health Surveillance | 2 | 2020 | 3129 | 0.09 | Why? |
| Vaccines, Attenuated | 3 | 2020 | 952 | 0.09 | Why? |
| Travel | 2 | 2020 | 7220 | 0.09 | Why? |
| Urban Population | 1 | 2018 | 2000 | 0.09 | Why? |
| Geographic Mapping | 2 | 2018 | 247 | 0.08 | Why? |
| Linear Models | 1 | 2012 | 1914 | 0.08 | Why? |
| Rural Population | 1 | 2018 | 2408 | 0.08 | Why? |
| Humans | 34 | 2021 | 930598 | 0.08 | Why? |
| Carrier State | 1 | 2017 | 2100 | 0.07 | Why? |
| Antibodies, Viral | 4 | 2018 | 51949 | 0.07 | Why? |
| Adolescent | 12 | 2021 | 86841 | 0.07 | Why? |
| Spatio-Temporal Analysis | 2 | 2020 | 1182 | 0.06 | Why? |
| Genomics | 1 | 2014 | 3118 | 0.06 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.06 | Why? |
| Viral Vaccines | 2 | 2020 | 7560 | 0.06 | Why? |
| Public Health | 2 | 2018 | 16359 | 0.06 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.06 | Why? |
| Epidemiological Monitoring | 1 | 2014 | 3493 | 0.06 | Why? |
| Computer Simulation | 2 | 2020 | 4982 | 0.05 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.05 | Why? |
| Administration, Oral | 2 | 2018 | 2340 | 0.05 | Why? |
| Young Adult | 9 | 2021 | 93724 | 0.05 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.05 | Why? |
| Senegal | 1 | 2019 | 283 | 0.05 | Why? |
| United States Virgin Islands | 1 | 2018 | 8 | 0.05 | Why? |
| Insecticide Resistance | 1 | 2018 | 27 | 0.05 | Why? |
| Neisseria meningitidis, Serogroup A | 1 | 2017 | 5 | 0.05 | Why? |
| Treatment Outcome | 4 | 2018 | 51732 | 0.05 | Why? |
| Insect Repellents | 1 | 2018 | 23 | 0.05 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.04 | Why? |
| Arboviruses | 1 | 2018 | 76 | 0.04 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.04 | Why? |
| Software | 1 | 2010 | 2501 | 0.04 | Why? |
| Placebo Effect | 1 | 2018 | 108 | 0.04 | Why? |
| Mali | 1 | 2017 | 181 | 0.04 | Why? |
| Honduras | 1 | 2017 | 117 | 0.04 | Why? |
| Siblings | 1 | 2018 | 226 | 0.04 | Why? |
| Risk Assessment | 2 | 2018 | 25439 | 0.04 | Why? |
| Puerto Rico | 1 | 2017 | 177 | 0.04 | Why? |
| Boston | 1 | 2020 | 929 | 0.04 | Why? |
| Male | 15 | 2021 | 367725 | 0.04 | Why? |
| Female | 15 | 2021 | 380317 | 0.04 | Why? |
| Meningitis, Meningococcal | 1 | 2017 | 114 | 0.04 | Why? |
| China | 5 | 2021 | 50654 | 0.04 | Why? |
| Americas | 1 | 2017 | 418 | 0.04 | Why? |
| Adult | 11 | 2021 | 244371 | 0.04 | Why? |
| Family | 2 | 2020 | 2909 | 0.04 | Why? |
| Culicidae | 1 | 2017 | 239 | 0.04 | Why? |
| Microcephaly | 1 | 2017 | 181 | 0.04 | Why? |
| Metagenome | 1 | 2017 | 268 | 0.04 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2018 | 801 | 0.03 | Why? |
| Protective Clothing | 1 | 2018 | 468 | 0.03 | Why? |
| Animals | 6 | 2018 | 78931 | 0.03 | Why? |
| Privacy | 1 | 2020 | 636 | 0.03 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.03 | Why? |
| Incidence | 3 | 2021 | 25622 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Infant, Newborn | 3 | 2021 | 23105 | 0.03 | Why? |
| Risk Factors | 5 | 2021 | 71621 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Seroepidemiologic Studies | 2 | 2018 | 10017 | 0.03 | Why? |
| Colombia | 1 | 2017 | 1241 | 0.03 | Why? |
| Public Health Practice | 1 | 2020 | 945 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2017 | 1638 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| History, 21st Century | 1 | 2018 | 1849 | 0.03 | Why? |
| Bangladesh | 1 | 2017 | 1620 | 0.03 | Why? |
| Students | 2 | 2018 | 5255 | 0.03 | Why? |
| Cohort Studies | 3 | 2018 | 36005 | 0.03 | Why? |
| Pharynx | 1 | 2017 | 1544 | 0.03 | Why? |
| Brazil | 2 | 2017 | 12582 | 0.02 | Why? |
| Aged | 4 | 2021 | 215776 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.02 | Why? |
| Bayes Theorem | 1 | 2018 | 3237 | 0.02 | Why? |
| Program Evaluation | 1 | 2017 | 1929 | 0.02 | Why? |
| Income | 1 | 2018 | 1564 | 0.02 | Why? |
| Age Factors | 2 | 2021 | 21039 | 0.02 | Why? |
| Communicable Disease Control | 1 | 2017 | 29620 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2021 | 4002 | 0.02 | Why? |
| Epidemics | 2 | 2018 | 6407 | 0.02 | Why? |
| Internationality | 1 | 2020 | 3297 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Middle Aged | 6 | 2021 | 270681 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2018 | 2585 | 0.02 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| Vaccines, Synthetic | 1 | 2018 | 3231 | 0.02 | Why? |
| United States | 3 | 2018 | 46150 | 0.02 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Health Policy | 1 | 2020 | 6242 | 0.01 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| Genome, Viral | 1 | 2017 | 13157 | 0.01 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.01 | Why? |
| Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |